Back Hepatitis C

Hepatitis C

IAS 2017: Hepatitis C treatment is Effective and Feasible in Africa

Treatment for hepatitis C in sub-Saharan Africa can produce cure rates as high as those seen in industrialized countries, with high adherence and minimal side effects, according to a presentation this week at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris.

alt

FDA Approves Gilead's Vosevi Combo Pill for Hepatitis C Re-treatment

On July 18, the U.S. Food and Drug Administration(FDA) approved Gilead Sciences' Vosevi, a new once-daily combination pill containing sofosbuvir, velpatasvir, and voxilaprevir. Vosevi was approved as "salvage therapy" for people with all hepatitis C virus (HCV) genotypes who were not previously cured with prior direct-acting antiviral therapy.

alt

HR17: Hepatitis C Virus Reinfection Is Uncommon After Being Cured with DAAs

Most people on opiate substitution therapy were successfully treated for hepatitis C with an interferon-free regimen of grazoprevir/elbasvir (Zepatier), and only a small number became reinfected during 3 years of follow-up, researchers reported at the 25th Harm Reduction International Conference this week in Montreal.

alt

San Francisco Task Force Releases First Hepatitis C Prevalence Estimates

End Hep C SF, a consortium of public health workers, medical providers, advocates, and people living with hepatitis C, has released the first-ever estimate of the number of people thought to be living with active hepatitis C virus (HCV) infection in San Francisco. 

alt

New Hepatitis C Infections in U.S. Tripled Over Past 5 Years, CDC Says

The U.S. Centers for Disease Control and Prevention (CDC) released new data last week showing that the number of new hepatitis C virus (HCV) infections reported to the agency nearly tripled between 2010 and 2015. A related study saw a rising rate of hepatitis C among pregnant women -- increasing the likelihood of mother-to-child HCV transmission -- while another showed that many states are not doing all they could to reduce new infections.

alt

HR17: Indonesian Buyers Club Helps People Obtain Generic Hepatitis C Treatment

A community-led buyers club in Indonesia has helped more than 100 people get generic direct-acting antiviral drugs to treat hepatitis C and is seeing a high cure rate, according to a presentation at the 25th Harm Reduction International Conference this month in Montreal.

alt

PAS 2017: Sofosbuvir Plus Ribavirin Cures Teens with Genotype 2 or 3 Hepatitis C

A 2-drug regimen of sofosbuvir (Sovaldi) and ribavirin taken for 12 weeks led to sustained virological response in all treated adolescents with hepatitis C virus (HCV) genotype 2, while a 24-week course cured all but one teen with harder-to-treat genotype 3, according to a presentation at the 2017 Pediatric Academic Societies Meeting last week in San Francisco.

alt

EASL 2017: Triple Combination Cures Most Hepatitis C Patients with Prior DAA Failure

Almost all people with genotype 1 hepatitis C who were previously unsuccessfully treated with a course of interferon-free direct-acting antiviral therapy achieved sustained response when retreated with a 3-drug combination being developed by Merck, researchers reported at the EASL International Liver Congress last month in Amsterdam.

alt